Immune Benefits of Consumption of Dairy Yogurt in Elderly

February 9, 2017 updated by: Yonsei University

Immune Benefits of Consumption of Dairy Yogurt Containing Functional Probiotics Among Individuals Over 60 Years Old

To investigate the impact of consuming dairy yogurt on immun function including natural killer (NK) cell activity, circulating levels of cytokines, and immunoglobulin (Ig) in elderly.

Study Overview

Detailed Description

A randomized, open-labelled, placebo-controlled study was conducted on 200 nondiabetic, nonobese and elderly (≥60 years) subjects. Over a twelve-week period, the test group consumed one bottle (120 mL) of dairy yogurt each day, whereas the placebo group consumed same volume of low fat milk daily. NK cell activity (%) was measured based on the ratios of effector cells (E; peripheral blood mononuclear cells, PBMCs) from each participant to target cells (T; K562 cells) at E:T= 10:1, 5:1, 2.5:1, 1.25:1 or 0.625:1. In addition, cytokines and immunoglobulin levels measured using commercial kits as manufacturer's instruction.

Study Type

Interventional

Enrollment (Actual)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Able to give informed consent
  • Over 60 years old without any health problems
  • The levels of white blood cells within range 4x10^3/μL~10x10^3/μL

Exclusion Criteria:

  • Individuals who get a cold
  • Diabetes
  • Hypersensitivity or disease history for milk protein
  • Epilepsy, neurological, or psychological disease
  • Alcoholism or drug addiction
  • Liver disease or severe kidney failure disease
  • Inflammation-related disease
  • Consumption of other test products or drugs within 1 month prior to screening
  • Regular consumption of immune-related functional foods including yogurt or milk within 1 month prior to screening
  • History of inflammation-related disease or taking medication to treat inflammation-related disease within 1 month prior to screening
  • History of cancer within 5 years
  • Any inappropriate condition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo group
Placebo supplementation
120 mL of low-fat milk
Experimental: Test group
Probiotic yogurt supplementation
120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Natural killer cell activity
Time Frame: At baseline
At baseline
Natural killer cell activity
Time Frame: At 12-week follow-up
At 12-week follow-up
Change from baseline natural killer cell activity at 12-week
Time Frame: At baseline and 12-week follow-up
At baseline and 12-week follow-up

Secondary Outcome Measures

Outcome Measure
Time Frame
White blood cell
Time Frame: At baseline
At baseline
Interleukin-12
Time Frame: At baseline
At baseline
Interferon-gamma
Time Frame: At baseline
At baseline
White blood cell
Time Frame: At 12-week follow-up
At 12-week follow-up
Change from baseline white blood cell at 12-week
Time Frame: At baseline and 12-week follow-up
At baseline and 12-week follow-up
Interleukin-12
Time Frame: At 12-week follow-up
At 12-week follow-up
Change from baseline Interleukin-12 at 12-week
Time Frame: At baseline and 12-week follow-up
At baseline and 12-week follow-up
Interferon-gamma
Time Frame: At 12-week follow-up
At 12-week follow-up
Change from baseline Interferon-gamma at 12-week
Time Frame: At baseline and 12-week follow-up
At baseline and 12-week follow-up
Immunoglobulin
Time Frame: At baseline
At baseline
Immunoglobulin
Time Frame: At 12-week follow-up
At 12-week follow-up
Change from baseline immunoglobulin at 12-week
Time Frame: At baseline and 12-week follow-up
At baseline and 12-week follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jong Ho Lee, Yonsei University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 28, 2016

Primary Completion (Actual)

January 10, 2017

Study Completion (Actual)

February 8, 2017

Study Registration Dates

First Submitted

February 9, 2017

First Submitted That Met QC Criteria

February 9, 2017

First Posted (Actual)

February 13, 2017

Study Record Updates

Last Update Posted (Actual)

February 13, 2017

Last Update Submitted That Met QC Criteria

February 9, 2017

Last Verified

February 1, 2017

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe